Aspire files patent application for clopidogrel sublingual powder formulation

Aspire Biopharma (ASBP) announced the filing of a new provisional patent application with the United States Patent and ...

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel.
Healio

Sublingual epinephrine film moving forward, NDA anticipated by early next year

Please provide your email address to receive an email when new articles are posted on . Aquestive aims to submit a new drug application in the first quarter of 2025. The company hopes to launch in ...
Seeking Alpha

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, ...
The Barre-Montpelier Times Argus

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized ...
Medscape

Subcutaneous Versus Sublingual Immunotherapy for Allergic Rhinitis and/or Asthma

Subcutaneous allergen-specific immunotherapy has long been used in allergic rhinitis and/or asthma and has been recognized to be efficacious. However, owing to the inconvenience of injection and the ...
The Journal News

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial ...

ESTERO, FLORIDA / ACCESS Newswire / September 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug delivery technology, ...
Monthly Prescribing Reference

Epinephrine Sublingual Film Under Review for Severe Allergic Reactions

A Prescription Drug User Fee Act target date of January 31, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for epinephrine ...